Hwail Pharm Co Ltd
KOSDAQ:061250
Hwail Pharm Co Ltd
Research & Development
Hwail Pharm Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hwail Pharm Co Ltd
KOSDAQ:061250
|
Research & Development
-₩788.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Yuhan Corp
KRX:000100
|
Research & Development
-₩197B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-19%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Research & Development
-₩162.2B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Research & Development
-₩189.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Research & Development
-₩8.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Research & Development
-₩5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Hwail Pharm Co Ltd
Glance View
HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 149 full-time employees. The company went IPO on 2002-04-18. The firm produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Hwail Pharm Co Ltd's Research & Development?
Research & Development
-788.2m
KRW
Based on the financial report for Sep 30, 2025, Hwail Pharm Co Ltd's Research & Development amounts to -788.2m KRW.
What is Hwail Pharm Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-6%
Over the last year, the Research & Development growth was -12%. The average annual Research & Development growth rates for Hwail Pharm Co Ltd have been -6% over the past three years , -2% over the past five years , and -6% over the past ten years .
